Changes in Hong Kong stocks | Cinda Biotech (01801) opened more than 6%, and net profit for the first half of the year increased by more than 50% year on year, 2030 revenue target of 35 billion to 40 billion yuan

The Zhitong Finance App learned that Cinda Biotech (01801) opened more than 6% higher. As of press release, it rose 6.49% to HK$106.6, with a turnover of HK$28.728,700.

According to the news, Cinda Biotech announced its 2026 interim results, measured according to International Financial Reporting Standards (IFRS): total revenue of 8.618 billion yuan (RMB, same below), up 44.8% year on year, of which product revenue was RMB 8.202 billion, up 56.7% year on year; profit for the period was 1,253 billion yuan, up 50.2% year on year. Net profit for the first half of the year has already exceeded the full year of 2025. This strong performance is due to the continued effectiveness of the “two-wheel drive” strategy for oncology and chronic diseases. Currently, the company's commercial product matrix has been expanded to 20 models.

In this semi-annual report, Cinda Biotech also clarified its 2030 development goals and strives to achieve total revenue of 35 billion to 40 billion yuan by 2030. In terms of global innovation, by 2030, at least 5 molecules will be promoted to enter global multi-center phase III research, and products will be marketed in key markets in Europe and the US, and overseas product revenue will begin to contribute. At the same time, Cinda Biotech officially announced the company's third major strategic transformation: from a leading biopharmaceutical company in China to a world-class biopharmaceutical company with global competitiveness.